Hemophilia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Patient Voices: Hemophilia - New York Times



New York Times
 
Patient Voices: Hemophilia 
New York Times
Val Bias, chief executive of the National Hemophilia Foundation, has severe factor 9 deficiency hemophilia. He has two older brothers who do not have a bleeding disorder, but he had other brothers who were born with the disease and didn't live long. As ...

 


Possible hemophilia cure under study in Israeli hospital - ISRAEL21c



ISRAEL21c
 
Possible hemophilia cure under study in Israeli hospital 
ISRAEL21c
BioMarin has chosen Sheba to take part in the next phase of international trials for what's being touted as a ?magic bullet? cure for hemophilia A, a genetic blood-clotting deficiency that results in patients bleeding longer after an injury and more ...

 


BioMarin's chief calls hemophilia treatment results 'extremely encouraging' - CNBC



CNBC
 
BioMarin's chief calls hemophilia treatment results 'extremely encouraging' 
CNBC
Despite the progress in its hemophilia treatment, the company's shares have only climbed 2 percent in the past 12 months. To be sure, while only a small number of patients have received the treatment to date, Bienaime said that such a dramatic increase ...

and more » 


Adynovi Receives EU Marketing Authorization for Hemophilia A Teens, Adults - Hemophilia News Today



Adynovi Receives EU Marketing Authorization for Hemophilia A Teens, Adults 
Hemophilia News Today
Shire recently received marketing authorization from the European Commission for Adynovi [antihemophilic factor (recombinant) PEGylated], enabling access for adults and adolescents throughout Europe seeking treatment for hemophilia A. Adynovi is an ...

 


A gamer's wish granted: Boy with hemophilia gets the video game setup of his dreams - Juneau Empire



Juneau Empire
 
A gamer's wish granted: Boy with hemophilia gets the video game setup of his dreams 
Juneau Empire
One of the things that makes this 6-year-old unique, though, is the very same thing that got him a total room makeover this weekend: Graysen has hemophilia. Nominated by a nurse, Graysen was the recipient of a Make-a-Wish Foundation wish fulfillment ...

and more » 


Sanofi to market new hemophilia drug in deal with Alnylam - Reuters



Reuters
 
Sanofi to market new hemophilia drug in deal with Alnylam 
Reuters
Under the agreement, Sanofi will obtain global development and commercialization rights to fitusiran, currently in development for the treatment of people with hemophilia A and B. Global commercialization of fitusiran will be done by Sanofi Genzyme ...
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran Endpoints News
Alnylam retools Sanofi deal to take full control of patisiran FierceBiotech
Sanofi, Alnylam Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance Drug Discovery & Development

all 27 news articles » 


uniQure Gene Therapy AMT-060 Shows Long-term Efficacy in Hemophilia B Patients - Hemophilia News Today



uniQure Gene Therapy AMT-060 Shows Long-term Efficacy in Hemophilia B Patients 
Hemophilia News Today
Gene therapy company uniQure released new data showing that its lead therapy AMT-060 for severe and moderately severe hemophilia B is safe and effective for up to two years, with adults requiring fewer doses of replacement therapy and showing a marked ...

 


Roche makes headway in hemophilia as UK grants early access to Hemlibra - FiercePharma



FiercePharma
 
Roche makes headway in hemophilia as UK grants early access to Hemlibra 
FiercePharma
Roche makes headway in hemophilia as U.K. grants early access to Hemlibra. by Arlene Weintraub |. Jan 5, 2018 9:21am. Roche logo. The Medicines and Healthcare Regulatory Agency in the U.K. says hemophilia A patients should get early access to Roche's ...

and more » 


Shire granted EU marketing authorization for ADYNOVIŽ [Antihemophilic Factor (Recombinant), PEGylated] for adults ... - GlobeNewswire (press release)



PharmaTimes
 
Shire granted EU marketing authorization for ADYNOVIŽ [Antihemophilic Factor (Recombinant), PEGylated] for adults ... 
GlobeNewswire (press release)
Zug, Switzerland - January 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI [Antihemophilic Factor ...
BRIEF?EU approval at last for Shire's long-acting hemophilia A therapy The Pharma Letter
Shire's Adynovi Treatment Granted Marketing Authorisation In EU London South East (blog)

all 4 news articles » 


FDA Approves Emicizumab-kxwh for Hemophilia A - ModernMedicine



ModernMedicine
 
FDA Approves Emicizumab-kxwh for Hemophilia A 
ModernMedicine
In November 2017, the FDA approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors. Replacement of ...